Novo Nordisk A/S said the supply of its blockbuster obesity medicine Wegovy will continue to be restricted in the US as the drugmaker struggles to expand production.

The Danish company made the comments even as it raised its profit and sales outlook for the year as demand for Wegovy and another related diabetes medicine fuel revenue growth. The stock fell as much as 2.2% in Copenhagen.

The supply challenge is raising questions about whether the drugmaker can stay on top of the wave that’s boosted its market value to about $420 billion — more than Denmark’s gross domestic product …